WallStSmart

Burning Rock Biotech Ltd (BNR)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IDEXX Laboratories Inc generates 785% more annual revenue ($4.55B vs $514.43M). IDXX leads profitability with a 25.0% profit margin vs -11.5%. IDXX earns a higher WallStSmart Score of 63/100 (C+).

BNR

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 7.5
Piotroski: 6/9Altman Z: -4.98

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 10.0Value: 2.7Quality: 7.0
Piotroski: 6/9Altman Z: 5.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BNR.

IDXXSignificantly Overvalued (-48.7%)

Margin of Safety

-48.7%

Fair Value

$436.26

Current Price

$504.70

$68.44 premium

UndervaluedFair: $436.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BNR2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.1010/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

IDXX4 strengths · Avg: 9.8/10
Return on EquityProfitability
70.7%10/10

Every $100 of equity generates 71 in profit

Operating MarginProfitability
35.0%10/10

Strong operational efficiency at 35.0%

Altman Z-ScoreHealth
5.9210/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.0%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

BNR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$129.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-10.7%2/10

ROE of -10.7% — below average capital efficiency

Revenue GrowthGrowth
-18.9%2/10

Revenue declined 18.9%

IDXX3 concerns · Avg: 2.7/10
P/E RatioValuation
36.5x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.932/10

Expensive relative to growth rate

Price/BookValuation
24.7x2/10

Trading at 24.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BNR

The strongest argument for BNR centers on Debt/Equity, Price/Book.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.0% and operating margin at 35.0%.

Bear Case : BNR

The primary concerns for BNR are EPS Growth, Market Cap, Return on Equity.

Bear Case : IDXX

The primary concerns for IDXX are P/E Ratio, PEG Ratio, Price/Book.

Key Dynamics to Monitor

BNR profiles as a turnaround stock while IDXX is a mature play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.54 — expect wider price swings.

IDXX is growing revenue faster at 9.7% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (63/100 vs 31/100), backed by strong 25.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Burning Rock Biotech Ltd

HEALTHCARE · DIAGNOSTICS & RESEARCH · China

Burning Rock Biotech Limited primarily develops and provides screening tests for cancer therapies in the People's Republic of China. The company is headquartered in Guangzhou, China.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?